1 mg)

DRUG4 trials

Sponsors

Hospices Civils De Lyon, Assistance Publique Hopitaux De Paris, Stichting Radboud University Medical Center, Centre Hospitalier Et Universitaire De Limoges

Conditions

CandidemiaPost-aggressive immunosuppressionSustained immunosuppressionVentilator acquired pneumonia

Phase 2

Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia

Not yet recruitingCTIS2024-510816-55-00

Stichting Radboud University Medical CenterCandidemia

Target: 125Updated: 2025-04-02

Phase 3

Human recombinant interferon gamma in the treatment of ventilator-acquired pneumonia in ICU patients. IGNORANT study

RecruitingCTIS2022-502229-16-00

Hospices Civils De LyonVentilator acquired pneumonia

Start: 2023-06-19Target: 132Updated: 2025-08-25

INFINITY - Effect of interferon gamma as a treatment for post-aggressive immunosuppression in intensive care units, a randomized Bayesian double-blind controlled trial versus placebo

Not yet recruitingCTIS2023-506725-11-00

Assistance Publique Hopitaux De ParisPost-aggressive immunosuppression

Target: 170Updated: 2025-10-24

Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial

RecruitingCTIS2024-516780-93-00

Centre Hospitalier Et Universitaire De LimogesSustained immunosuppression

Start: 2025-07-09Target: 326Updated: 2025-05-27

Related Papers

Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial.

2026-01-27